MyFinsight
Home
Blog
About
Maturities of marketable
securities
$16,221K
(-59.28%↓ Y/Y)
Proceeds from issuance of
common stock
$25K
(78.57%↑ Y/Y)
Proceeds from sales of
property and equipment
$717K
(-25.55%↓ Y/Y)
Net cash provided by
investing activities
$15,695K
(-38.07%↓ Y/Y)
Net cash provided by
financing activities
$25K
(78.57%↑ Y/Y)
Canceled cashflow
$1,243K
Net increase
(decrease) in cash
$1,157K
(-51.71%↓ Y/Y)
Canceled cashflow
$14,563K
Purchases of marketable
securities
$1,230K
(-92.04%↓ Y/Y)
Purchases of property and
equipment
$13K
Non-cash lease expense
$1,347K
(8.72%↑ Y/Y)
Stock-based compensation
expense
$1,097K
(-17.77%↓ Y/Y)
Asset impairment
$808K
Depreciation and
amortization
$374K
(-49.87%↓ Y/Y)
Net cash used in
operating activities
-$14,563K
(36.58%↑ Y/Y)
Canceled cashflow
$3,626K
Net loss
-$14,964K
(23.66%↑ Y/Y)
Operating lease
liabilities
-$1,334K
(-30.02%↓ Y/Y)
Accounts payable and
accrued expenses
-$1,203K
(64.10%↑ Y/Y)
Prepaid expenses and
other assets
$160K
(-32.20%↓ Y/Y)
Accretion of discount on
marketable securities
$122K
(-67.81%↓ Y/Y)
Gain on sale of
property and equipment
$116K
(-59.72%↓ Y/Y)
Deferred revenue
-$2K
(99.87%↑ Y/Y)
Back
Back
Cash Flow
Bolt Biotherapeutics, Inc. (BOLT)
Bolt Biotherapeutics, Inc. (BOLT)
source: myfinsight.com